SANA BIOTECHNOLOGY INC. - COMMON STOCK

3,4050

24-января-25 15:36:28

15 мин. задержка

Акции

-0,0850

-2,44%

Сегодняшний диапазон

3,3300 - 3,6500

ISIN

N/A

Источник

NASDAQ

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

07 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

02 дек 2024 09:00:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology to Present at December 2024 Investor Conferences

25 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

08 ноя 2024 09:00:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

04 ноя 2024 16:30:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

30 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology to Present at September 2024 Investor Conferences

29 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

26 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

08 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions

21 май 2024 09:00:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

08 май 2024 16:05:01 Источник Nasdaq GlobeNewswire
Sana Biotechnology to Present at May and June 2024 Investor Conferences

06 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

29 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

28 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

13 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 фев 2024 16:05:48 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Pricing of Upsized Public Offering

08 фев 2024 01:22:20 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces Proposed Public Offering of Common Stock

07 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

05 янв 2024 09:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.